CVRx®, Inc.

About CVRx, Inc.

CVRx, Inc. is a privately held company founded in 2001 and headquartered in Minneapolis, Minnesota.  The company has developed the second generation Barostim, a minimally-invasive implantable system and the only device CE Marked for the separate indications of heart failure and resistant hypertension.  Barostim is commercially available in over 20 countries and under clinical evaluation for the treatment of heart failure and hypertension in the United States.It is now MR Conditional, or safe for use under specified conditions in Europe. The company’s previous device, Barostim neo legacy™, holds Humanitarian Device Exemption (HDE) approval from the FDA, deeming it safe for use in patients who were responders to the first-generation Barostim Therapy with Rheos Carotid Sinus Lead System.

About CVRx, Inc.

CVRx, Inc. is a privately held company founded in 2001 and headquartered in Minneapolis, Minnesota.  The company has developed the second-generation Barostim neo®, a minimally-invasive implantable system and the only device CE Marked for the separate indications of heart failure and resistant hypertension.  Barostim neo is commercially available in over 20 countries and under clinical evaluation for the treatment of heart failure and hypertension in the United States.

Category: 

Location
9201 West Broadway Avenue Suite 650
MN 55445 Minneapolis
United States
Phone: 416-2840
Fax: (763) 416-8402
US

Further resources

Products

Related articles

Related News

Related events

Related Videos